Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8735MR)

This product GTTS-WQ8735MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8735MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13638MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ11728MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ8528MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ864MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ2647MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ1301MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ12108MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ4626MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW